Regenxbio falls as Q4 loss widens

Regenxbio

05/03/2026 16:10

** Shares of drug developer Regenxbio RGNX.O fall 8.32% to $8.38

** Co posts Q4 loss of $1.30 per share, versus loss of $1.01 per share a year ago. Analysts were expecting a loss of 96 cents per share, according to data compiled by LSEG

** Posts Q4 revenue of $30.3 million, below analysts' estimate of $36.6 million

** R&D expenses for the quarter were $59.6 million, due to higher clinical trial expenses and manufacturing-related costs - RGNX

** RGNX shares had risen over 86% in 2025

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))